Protox Therapeutics Incorporated (“Protox”) today announced that it has entered into a manufacturing agreement with the Waisman Clinical BioManufacturing Facility (WCBF) at the University of Wisconsin-Madison to manufacture clinical batches of PSA-PA1, its lead product in development for the treatment of localized prostate cancer.
Month: October 2004
Citywide classes for 4-year-olds?
By Lee Sensenbrenner Reprinted by permission Reporting success with a four-year-old kindergarten pilot program, the Madison Metropolitan School District is beginning talks to determine what a citywide initiative might look like next fall. A committee …